NCT05784311 2024-10-21
SPARROW
Leiden University Medical Center
Phase 4 Recruiting
Clinical Trials
3 trialsNCT05462496 2024-10-15
Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer
Icahn School of Medicine at Mount Sinai
Phase 2 Recruiting
NCT03891979 2020-06-26
Gut Microbiome Modulation to Enable Efficacy of Checkpoint-based Immunotherapy in Pancreatic Adenocarcinoma
NYU Langone Health
Phase 4 Withdrawn